Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

Video

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Abhinav Deol, MD, associate clinical professor, Barbara Ann Karmanos Cancer Institute, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia (ALL).

Data have shown encouraging rates of complete remission (CR) among pediatric patients with ALL who are treated with CAR T-cell therapy, Deol says.

As such, CAR T-cell therapy may offer a potentially curative treatment option in this setting.

However, older patient​s with ALL who achieve a CR with CAR T-cell therapy require subsequent allogenic stem cell transplants to prevent relapse, Deol concludes.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.